AF
KRYS icon

Allworth Financial’s Krystal Biotech KRYS Stock Holding History

Allworth Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Buy
469
+421
+877% +$126K ﹤0.01% 1571
2026
Q1 		$12.4K Buy
48
+21
+78% +$5.59K ﹤0.01% 3360
2025
Q4 		$6.66K Buy
27
+7
+35% +$1.47K ﹤0.01% 3540
2025
Q3 		$3.53K Sell
20
-24
-55% -$3.59K ﹤0.01% 3730
2025
Q2 		$6.05K Buy
44
+18
+69% +$2.64K ﹤0.01% 3163
2025
Q1 		$4.4K Buy
26
+20
+333% +$3.36K ﹤0.01% 2833
2024
Q4 		$921 Sell
6
-1
-14% -$177 ﹤0.01% 3424
2024
Q3 		$1.27K Sell
7
-2
-22% -$386 ﹤0.01% 3136
2024
Q2 		$1.83K Buy
9
+3
+50% +$504 ﹤0.01% 2961
2024
Q1 		$1.07K Buy
6
+4
+200% +$556 ﹤0.01% 3057
2023
Q4 		$249 Hold
2
– – ﹤0.01% 3262
2023
Q3 		$232 Hold
2
– – ﹤0.01% 3210
2023
Q2 		$235 Hold
2
– – ﹤0.01% 3068
2023
Q1 		$161 Hold
2
– – ﹤0.01% 3051
2022
Q4 		$158 Hold
2
– – ﹤0.01% 2843
2022
Q3 		$0 Hold
2
– – ﹤0.01% 2887
2022
Q2 		$0 Buy
+2
New +$124 ﹤0.01% 2603

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allworth Financial's KRYS Position: Q2 2026 in Review

Allworth Financial increased its Krystal Biotech (KRYS) stake by 877% in Q2 2026, buying an estimated $126K and bringing the position to 469 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1571.

Allworth Financial first reported a position in KRYS in Q2 2022 and has held it in 17 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Allworth Financial held 469 shares of Krystal Biotech worth $174K as of Q2 2026.
  • Allworth Financial bought 421 Krystal Biotech shares in Q2 2026, an estimated $126K.
  • Krystal Biotech made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #1571 holding.
  • Allworth Financial first reported a position in Krystal Biotech in Q2 2022 and has held it in 17 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.